{"entity":{"id":"grn-1201","kind":"drug","name":"GRN-1201","aka":[],"tldr":"GRN-1201 is an experimental peptide vaccine from BrightPath Biotherapeutics, in phase 2 trials for melanoma and non-small cell lung cancer; its current status is not stated.","summary":"GRN-1201 is a peptide vaccine (4 peptides) from BrightPath Biotherapeutics. A cancer vaccine made of four peptides, tested in HLA-A*02 patients with resected melanoma and with pembrolizumab in PD-L1-positive metastatic NSCLC. Its furthest stage is phase 2, for melanoma and non-small cell lung cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 in melanoma completed; phase 2 with pembrolizumab in NSCLC terminated ('Recruitment rate too slow'). Not on the company's current pipeline page. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"BrightPath Biotherapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT02696356"},{"label":"BrightPath Biotherapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT03417882"},{"label":"BrightPath Biotherapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT03417882"},{"label":"ClinicalTrials.gov: trials of GRN-1201","url":"https://clinicaltrials.gov/search?intr=GRN-1201"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["brightpath-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct02696356","nct03417882"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"GRN-1201","modality":"Peptide vaccine (4 peptides)","mechanism":"A cancer vaccine made of four peptides, tested in HLA-A*02 patients with resected melanoma and with pembrolizumab in PD-L1-positive metastatic NSCLC.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/grn-1201/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"brightpath-biotherapeutics","kind":"company","name":"BrightPath Biotherapeutics","route":"/companies/brightpath-biotherapeutics/"}],"trial":[{"id":"nct03417882","kind":"trial","name":"GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC","route":"/trials/nct03417882/"},{"id":"nct02696356","kind":"trial","name":"Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma","route":"/trials/nct02696356/"}]}}